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Abstract
Holocarboxylase synthetase (HLCS) catalyzes the covalent attachment of biotin to cytoplasmic 
and mitochondrial carboxylases, nuclear histones, and over a hundred human proteins. 
Nonhydrolyzable ketophosphonate (β-ketoP) and hydroxyphosphonate (β-hydroxyP) analogs of 
biotin-5′-AMP inhibit holocarboxylase synthetase (HLCS) with IC50 values of 39.7 μM and 203.7 
μM. By comparison, an IC50 value of 7 μM was observed with the previously reported biotinol-5'-
AMP. The Ki values, 3.4 μM and 17.3 μM, respectively, are consistent with the IC50 results, and 
close to the Ki obtained for biotinol-5'-AMP (7 μM). The β-ketoP and β-hydroxyP molecules are 
competitive inhibitors of HLCS while biotinol-5'-AMP inhibited HLCS by a mixed mechanism.
Keywords
Biotin-5′-AMP; β-ketophosphonate; β-hydroxyphosphonate; holocarboxylase synthetase, 
biotinylation
Holocarboxylase synthetase (HLCS) is the sole enzyme in the human proteome capable of 
catalyzing the covalent attachment of biotin to lysine residues.1 HLCS localizes in the 
cytoplasm, mitochondria, and cell nuclei.1,2 HLCS catalyzes biotinylation of five 
carboxylases in mitochondria and cytoplasm, which play key roles in gluconeogenesis, fatty 
acid metabolism, and leucine metabolism.3 In addition, a recent mass spectrometry screen 
identified 108 novel biotinylated proteins; heat shock proteins and enzymes from glycolysis 
are overrepresented among these proteins.4 HLCS orchestrates the assembly of a 
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multiprotein gene repression complex in human chromatin, partially mediated through 
HLCS-dependent methylation of the histone methyltransferase EHMT1 and the nuclear 
receptor co-repressor N-CoR.5 Consistent with the importance of HLCS in intermediary 
metabolism and cell function, no living HLCS null person has ever been reported, and 
persons with HLCS mutations require lifelong treatment with pharmacological doses of 
biotin.6
HLCS-dependent biotinylation involves basically two steps (Fig. 1). In the first, activation 
of biotin by ATP generates the mixed anhydride biotin-5′-adenosine monophosphate 
(Bio-5′-AMP) (1). In the second step, the phosphate anhydride serves as an acylating agent 
for a target lysine in carboxylases (2), histones (3), and other proteins,3,4,7 covalently linking 
biotin to the substrate via an amide bond.
The objective of this study was to develop a new class of synthetic HLCS inhibitors which 
could potentially be targeted to distinct cellular structures. Such an inhibitor would be a 
useful analytical tool in studies of HLCS-dependent biotinylation events in the cytoplasm, 
mitochondria, and nucleus. We based these studies on analogs of biotin-5′-AMP, namely 
biotin β-ketophosphonate-5′-AMP (β-ketoP) and biotin β-hydroxyphosphonate-5′-AMP (β-
hydroxyP), that substitute a hydrolytically stable phosphonate for the acyl phosphate found 
in biotin-5′-AMP (Figure 2a). The use of phosphonates as unreactive isosteres of phosphates 
is well established.8 For example, nonhydrolyzable aminoacyl analogs of aspartyl adenylate 
exhibit potent inhibitory activity against E. coli aspartyl-tRNA synthetase.9 There is 
precedence for the efficacy of structurally analogous compounds sulfamides, sulfonamides, 
and 1,2,3-triazoles in the inhibition of a microbial biotin protein ligase, the HLCS ortholog 
BirA (Fig. 2b).10-13 We also investigated biotinol-5′-AMP, a known phosphate analog of 
biotin-5′-AMP which replaces the carbonyl oxygen with a methylene (CH2).10,14
Inhibitor synthesis: The central element of the synthesis is the formation of a protected 
version of a biotin ketophosphonate (4a) via condensation of a biotin-derived 
ketophosphonic acid (3) with a protected adenosine (Scheme 1). The synthesis begins with 
biotin methyl ester (1), prepared via the acid-catalyzed esterification of biotin.15 Reaction 
with the carbanion derived from methyl phosphonate was anticipated to offer a convenient 
route to a precursor of the desired phosphonates. However, reaction of ester 1 with the 
lithiated methylphosphonate, generated using lithium bis(trimethylsilyl)amide (LiHMDS) or 
n-butyl lithium (n-BuLi), resulted in poor yields. Fortunately, reaction of the ester with a 
large excess of the lithiated phosphonate, followed by quenching with deionized water to 
minimize demethylation of the phosphonate diester product, produced a 69% yield of 
dimethyl β-ketophosphonate 2.16 Selective monodemethylation with lithium bromide 
provides a good yield of mono ester 3. The pyridinium salt of 3 underwent coupling with 2′, 
3′-isopropylidineadenosine (i-PrA) in the presence of O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) to provide a mixed phosphonate diester 
(4a) in 79% yield for two steps.17,18 No coupling was observed if N,N'-
dicyclohexylcarbodiimide (DCC) was substituted for HBTU. The acidic methylene of the 
ketone phosphonate was observed (NMR) to readily undergo H/D exchange upon 
dissolution in d4-MeOH.
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Reduction of the ketone with NaBH4 resulted in formation of the corresponding alcohol (4b) 
as a mixture of diastereomers at the newly formed stereocenter. Stirring the ketone diester 
(4a) or the alcohol diester (4b) in pyridine/water resulted in selective demethylation to 
afford monoesters 5a or 5b, respectively. Removal of the acetonide protecting group from 
the sugar followed by neutralization with ammonium bicarbonate provided the target biotin 
β-ketophosphonate (β-ketoP) 6a in 58% yield for two steps. The same procedure, when 
applied to alcohol 5b, furnished biotin-β-hydroxyphosphonate (β-hydroxyP) 6b in 99% 
yield.
Inhibition of HLCS: Biotin β-ketophosphonate-5′-AMP (β - ketoP, 6a) inhibited HLCS in a 
dose-dependent manner. The polypeptide p67 is a substrate for biotinylation by HLCS.19 
When recombinant p67 was incubated with recombinant HLCS and 20 μM biotin in the 
presence of 50 to 500 μM β-ketoBP, HLCS inhibition was maximal at the highest inhibitor 
concentration tested. For example, the inhibition at 500 μM β-ketoBP was 81.3±11.1% 
(P<0.01; n=4) compared with vehicle control (Fig. 3A). Data are presented as mean±SD of 4 
replicates. Incubation of p67 in the absence of HLCS produced no detectable signal (lane 6 
in Fig. 3B). Under the conditions used here, IC50 and Ki for β-ketoBP equaled 39.7±1.9 μM 
and 2.0 ±0.1 μM, respectively; see Supplementary Materials for details regarding assays and 
calculations. When tested under identical conditions, β-hydroxyP inhibited HLCS activity by 
67.7 ±10.0% (P=0.0001; n=4) at concentrations of 500 μM inhibitor. The IC50 and Ki values 
calculated under these conditions were 203.7 ±3.7μM and 10.4±0.2μM, respectively. β-
KetoP is a competitive inhibitor of HLCS, based on competition studies with biotin. In these 
studies, the concentration of the inhibitor was held constant at 250 μM while that of biotin 
was varied from 0-320 μM; a second curve was generated in the absence of inhibitor (Fig. 
3C). The apparent Vmax was similar for incubations with and without inhibitor [31.5±1.6 vs. 
22.3±1.51 pmol biotinylated p67/(nmol HLCS x s); n=4] whereas the apparent Km for biotin 
was increased by the addition of inhibitor (77.9±10.3 vs. 1.6±1.8 μM biotin; N=4). β-
HydroxyP (6b) also acts as a competitive inhibitor as evidenced by similar apparent Vmax 
values with and without inhibitor [20.6±1.8 vs. 22.6±1.4 pmol biotinylated p67/nmol HLCS 
x s); n=4] whereas reactions incubated with inhibitor increased the apparent Km for biotin 
(82.5±20.4 vs. 1.9±1.8 μM biotin; n=4). As a negative control we conducted incubations 
with a biotin ketophosphonic acid (compound 3 in Scheme 1). This substrate incorporates an 
electrophilic carbonyl carbon beta to a charged phosphonate but lacks the adenosyl fragment 
hypothesized as essential for mediating HLCS inhibition. Consistent with this theory, the 
ketophosphonic acid compound did not inhibit HLCS (data not shown).
The results were compared against assays conducted with biotinol-AMP, a known phosphate 
analog of biotin-5′-AMP which has previously been employed for inhibition of BirA (biotin 
protein ligase).10,11 Biotinol-AMP reduces HLCS activity by 98.01±0.1% at concentrations 
of 500 μM and has an IC50 value and Ki of 8.8±3.6μM and 754±303nM, respectively. When 
reactions incubated with biotinol-AMP were challenged with increasing amounts of up to 
320 μM biotin, the apparent Vmax decreased compared to reactions without inhibitor 
(22.6±1.4 vs. 5.9±1.4; n=4) and Km increased (1.9±1.8 vs. 146±79; n=4) indicating the 
biotinol-AMP most likely acts as a mixed inhibitor. There remains limited knowledge 
regarding the structure of HLCS and the mechanism of catalysis.11,13b,20 Similarly, little is 
Sittiwong et al. Page 3
Bioorg Med Chem Lett. Author manuscript; available in PMC 2015 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
known about the basis for selectivity between the classic carboxylase targets of HLCS and 
novel targets in chromatin and other proteins. The objective of this study was to develop a 
synthetic HLCS inhibitor capable of penetrating cell membranes and which could potentially 
be targeted to distinct cellular structures. Such an inhibitor would be a useful analytical tool 
in studies of carboxylase biotinylation in cytoplasm and mitochondria, studies of chromatin 
protein biotinylation and HLCS-dependent formation of multiprotein gene repression 
complexes in nuclei, and studies of newly discovered species of biotinylated proteins 
throughout the cell.
Consistent with the importance of HLCS in intermediary metabolism and epigenetics, no 
living HLCS null individual has ever been reported, suggesting embryonic lethality. HLCS 
knockdown in Drosophila melanogaster (~30% residual activity) produces phenotypes such 
as decreased life span and reduced heat resistance.21 Mutations and single nucleotide 
polymorphisms have been identified and characterized in the human HLCS gene; these 
mutations cause a substantial decrease in HLCS activity, aberrant gene regulation and 
metabolic abnormalities.6,22 Unless diagnosed and treated at an early stage, homozygous 
severe HLCS deficiency is characteristically fatal.23 Three independent cancer and patent 
databases correlate HLCS loss or mutation with an increase in detected tumors.24
Several classes of biotin-5′-AMP analogs have been applied to study the function of biotin 
protein ligases (BPLs), exemplified by HLCS as well as BirA, an enzyme catalyzing 
biotinylation of acyl carrier protein in prokaryotes.10,13,14 BirA from E. coli has 21% 
sequence similarity to HLCS.25 Biotinol-5′-AMP, a phosphate ester lacking the acyl 
carbonyl of biotin-5′-AMP, binds tightly to the Escherichia coli biotin repressor (KD = 1.5 ± 
0.2 nM)11,20 and inhibits biotin transfer to the acceptor protein.10,14 Biotinol-5′-AMP also 
binds tightly to Staphylococcus aureus BPL (Ki = 0.03 ± 0.01 μM). The activity of this 
analog would appear to suggest the key role of the phosphate moiety and the relative lack of 
importance of hydrogen-bonding interactions to the acyl carbonyl of biotin-5′-AMP. 
However, other work has demonstrated that a sulfamoyl-containing bisubstrate analog, 
replacing the acyl phosphate with an acyl sulfonamide, strongly binds Mycobacteria 
tuberculosis BPL (MtBPL); a co-crystal revealing multiple hydrogen-bonding interactions 
between the protein and the acyl sulfonamide.12 More recently, a biotin-5′-AMP analog 
replacing the acyl phosphate with a 1,2,3-triazole was found to bind tightly to BPL and 
exhibit >1100-fold selectivity for the S. aureus BPL over the human homologue.13 This 
suggests the possibility of designing potent inhibitors of bacterial BPL. However, no similar 
approach has been used to study the function of HLCS or human BPL.
A model of the HLCS/biotin-5′-AMP complex as well as the crystal structure of biotin-5′-
AMP with BPL from Pyrococcus horikoshii OT3 (pdb:1wqw) suggests the importance of 
hydrogen bonding involving the carbonyl and phosphonate oxygen (Figure S1).13b,26 The β-
ketophosphonate and β-hydroxyphosphonate analogs introduced here maintain the natural 
charge state of biotin-AMP and place a basic oxygen atom beta to the phosphonate group. 
However, in contrast to the BirA inhibitors described above, the ketophosphonate (β-ketoP, 
6) incorporates an electrophilic carbon at the location of the original acyl group in biotin-5′-
AMP. Although the reduced activity of the new inhibitors compared with biotinol-AMP 
suggests that preservation of an electrophilic center (C=O) or hydrogen bonding group 
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(CHOH) beta to phosphonate is of limited importance in inhibitor design, we note that the 
1,2,3-triazole analogs completely lacking a carbonyl group show no inhibition toward 
human BPL. It is also possible that conformational differences between the acyl phosphate 
of biotin-5′-AMP and the phosphonate of 6a and 6b might also contribute to the reduced 
binding observed.
In conclusion, we have described a new class of inhibitors of holocarboxylase synthetase 
HLCS based upon replacement of the ester of biotin-5′-AMP with a ketone or a secondary 
alcohol. The analogs produce significant levels of inhibition with isolated enzyme. Efficacy 
of the new inhibitors in vivo has not been tested and further investigations are warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
HLCS catalysis
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Figure 2. 
a. Chemical structure of biotin-5′-AMP and ketophosphonate (6a) and hydroxyphosphonate 
(6b) analogs; b. reported sulfamoyl, sulfonamide, triazole, and phosphate inhibitors.
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Scheme 1. 
Synthesis of ketophosphonate (β-ketoP) and hydroxyphosphonate (β-hydroxyP) analogs of 
biotin-5′-AMP
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Figure 3. 
Inhibition of HLCS by biotin β-ketophosphonate-5′-AMP. (A) HLCS activity was quantified 
using infrared absorbance in the presence of 20 μM biotin and various concentrations of 
biotin β-ketophosphonate-5′-AMP (One way-ANOVA; *P<0.05; N=4; Dunnett’s multiple t-
test *p<0.05, **p<0.01, ***p<0.001). (B) Representative gel, depicting biotinylation of p67 
in the presence of various concentrations of biotin β-ketophosphonate-5′-AMP. Lane 6 
shows p67 incubated in the absence of HLCS. (C) Competitive inhibition of HLCS by biotin 
β-ketophosphonate-5-AMP.
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Supporting Information:  -Keto and -hydroxyphosphonate analogs of biotin-
5’-AMP are inhibitors of holocarboxylase synthetase 
 
 
Experimental Procedures. General experimental procedures have been described.1  
Biotin methyl ester.2  Acetyl chloride (0.6 mL, 7 mmol) was added dropwise to 4 mL of 
methanol in a round bottom flask held at 0 oC. After stirring for 15 min., the solution was then 
added to a room temp suspension of biotin (0.5068 g, 2.1 mmol) in methanol (4 mL) and the 
reaction was stirred until the biotin was completely consumed (TLC, ~30 min.). Solvent was 
removed under reduced pressure and the residue was partitioned between sat. NaHCO3 and 5% 
methanol in dichloromethane. The separated organic layer was dried over MgSO4 and 
evaporated under vacuum to obtain compound 1 as a white solid (0.5226 g, 98%): []25D = +63 
(c = 0.15, reagent grade CHCl3); mp 156-157 
oC; Rf = 0.59 (10% MeOH in CH2Cl2); IR (ZnSe) 
3267, 3193, 2927, 2849, 1744, 1702, 1462, 1431 cm-1; 1H NMR (DMSO, 400 MHz): δ 4.31 (dd, 
J = 5.2, 7.7 Hz, 1H), 4.13 (ddd, J = 1.8, 4.4, 7.7 Hz, 1H), 3.59 (s, 3H), 3.10 (ddd, J = 4.4, 6.1, 8.4 
Hz, 1H), 2.83 (dd, J = 5.1, 12.4 Hz, 1H), 2.58 (d, J = 12.4 Hz, 1H), 2.31 (t, J = 7.4 Hz, 3H), 
1.61-1.30 (m, 6H); 13C NMR (DMSO, 100 MHz, WS-3-37) δ 173.8, 163.2, 61.5, 59.6, 55.8, 
51.7, 33.5, 28.5, 28.4, 24.9. 
 
Dimethyl-2-oxo-6-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) 
hexylphosphonate (2) To a solution of dimethyl methylphosphonate (1.08 mL, 9.9 mmol) in 40 
mL anhydrous THF was added dropwise n-BuLi (nominally 1.6 M in hexane, 6.25 mL, 9.9 
mmol) at -78 oC. The reaction was stirred for 5-10 min and then added to a -78 oC suspension of 
biotin methyl ester (1, 0.2557 g, 0.99 mmol) in 5 mL THF via cannula. The reaction was stirred 
for 30 min. The cooling bath was removed and the reaction was allowed to warm to room 
temperature over 20 min. Deionized water (~4.5 mL) was added until the mixture turned clear. 
The solution was then concentrated and the residue was purified by flash chromatography using 
a gradient of 5/10 % MeOH in CH2Cl2 to afford compound 2 as a white solid (0.2386 g, 69%): 
[]25D = +20 (c 0.06, reagent grade CH2Cl2); mp. 93-94 oC; Rf = 0.41 (10% MeOH/ CH2Cl2); IR 
(ZnSe) 3248, 2923, 2852, 1697, 1680, 1463, 1253, 1030, 815 cm-1; 1H NMR (CDCl3, 600 MHz, 
WS-2-51A-31P): δ 6.53 (s, 1H), 5.65 (s, 1H), 4.48 (dd, J = 5.2, 7.7 Hz, 1H), 4.28 (ddd, J = 1.0, 
4.7, 7.4 Hz, 1H), 3.78 (d, J = 11.2 Hz, 3H), 3.77 (d, 3J(H,P) = 11.2 Hz, 3H), 3.17 (dd, 2J(H,P) = 
22.8, 2J(H,H) = 13.8 Hz, 1H), 3.10 (dd, 2J(H,P) = 22.8, 2J(H,H) = 13.8 Hz, 1H), 3.12 (dt, J = 4.8, 
7.31H), 2.88 (dd, J = 4.8, 12.9 Hz, 1H), 2.72 (d, J = 12.9 Hz, 1H), 2.64 (dt, J = 2.8, 7.1 Hz, 2H), 
1.75-1.61 (m, 4H), 1.40 (q, J = 7.6 Hz, 2H); 13C NMR(CDCl3, 100 MHz) δ 202.3 (d, 2J (C,P)= 
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6.0 Hz),164.1, 61.8, 60.1, 55.7, 53.2 (d, 2J(C,P)= 6.0 Hz) 53.1 (d, 2J(C,P) = 7.0 Hz) 43.8, 41.0 (d, 
1J(C,P) = 127.0 Hz) 40.6, 28.3, 28.0, 23.4; 31P NMR (CDCl3, 162MHz) δ 23.2; HRESI-MS: 
calcd for 12C13
1H23
23Na14N2
16O5
35PS [M+Na]+: 373.0963; found: 373.0955.  
 
Methyl hydrogen 2-oxo-6-((6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) 
hexylphosphonate (3). A suspension of the dimethyl ketophosphonate (2, 0.1474 g, 0.42 mmol) 
and LiBr (0.073 g, 0.84 mmol) in anhydrous acetonitrile (8.4 mL) was stirred at 60 oC overnight. 
The resulting solution, containing a white precipitate, was concentrated and the residue was 
purified by flash chromatography (MeCN: H2O = 8:1 to 7:1) to afford compound 3 as a white 
solid (0.121g, 86 %); []25D = +130 (c = 0.075, MeOH); mp 226oC (decomp); Rf = 0.51 (50% 
MeOH/ CH2Cl2); IR (ZnSe) 3343, 2931, 2852, 2470, 1665, 1460, 1205, 1042 cm-1; 
1H NMR 
(MeOD, 400 MHz): δ .4.50 (dd, J = 4.3, 7.9 Hz, 1H), 4.33 (dd, J = 4.5, 7.9 Hz, 1H), 3.60 (d, 3J 
(H,P) = 11.0 Hz, 3H), 3.22 (ddd, J = 4.6, 6.0, 10.5 Hz, 1H), 2.96 (d, 2J (H,P)= 21.7 Hz, 2H), 2.94 
(dd, J = 4.8, 12.9 Hz, 1H), 2.73 (dt, J = 2.7, 7.4 Hz, 2H), 2.71 (d, J = 13.0 Hz, 1H), 1.80-1.71 (m, 
1H), 1.66-1.54 (m, 3H), 1.48-1.40 (m, 2H); 13C NMR (MeOD, 75 MHz) δ 207.1 (d, 2J (C,P) = 
5.0 Hz), 164.7, 61.9, 60.2, 55.6, 50.8 (d, 2J (C,P) = 6.0 Hz), 43.54 (d, 1J (C,P) = 115.0 Hz), 
42.44, 39.65, 28.17, 28.13, 23.05; 31P NMR (MeOD, 162MHz) δ 14.32; HRESI-MS: calcd for 
12C12
1H20
23Na2
14N2
16O5PS: [M-H+2Na]
+: 381.0626; found: 381.0625. 
 
((3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl methyl 2-oxo-6-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)hexylphosphonate (4a).  The ketophosphonic acid (3, 98.8 mg, 0.29 mmol) 
was co-evaporated with pyridine (2 x 2 mL) to give the pyridinium salt. A solution of the salt, 2′, 
3′-isopropylideneadenosine (0.3549 g, 1.15 mmol), O-benzotriazol-1-yl-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) (0.3493 mg, 0.92 mmol) and DMAP (40.1 
mg, 0.33 mmol) in anhydrous DMF (2.0 mL) was stirred at room temperature for 4 h. The 
mixture was then partitioned between 5% MeOH/CH2Cl2 and sat.  aq. NH4Cl. The organic layer 
was dried over Na2SO4 and the residue obtained upon concentration in vacuum was purified by 
flash column chromatography with 10% MeOH in dichloromethane. Rf = 0.44 (20% MeOH/ 
CH2Cl2); the compound was used for the next reaction without further purification. 
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((3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl methyl 2-hydroxy-6-((2RS, 3aS,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)hexylphosphonate (4b). To a 0 oC solution of the protected β-
ketophosphonate 3 (0.1900 g, 0.30 mmol) in 4:1 isopropanol:CH2Cl2 (10 mL) was added NaBH4 
(0.0460 g, 1.2 mmol). The reaction was warmed up to rt and stirred until no starting material 
remained (TLC ~ 30 min). The reaction was then cooled to 0 oC on ice bath and quenched with 
15 mL of sat. NaHCO3. The solution was stirred for 30 min and then extracted with CH2Cl2 
30mLx3. The organic layers were combined and dried over Na2SO4. The residue obtained upon 
concentration was purified by flash chromatography over silica gel (10% and 15% MeOH in 
CH2Cl2) to furnish a mixture of four diastereoisomers as a white solid (0.1563 g, 82%): mp 30-
40 oC; Rf = 0.39 (WS-3-58) (15% MeOH/CH2Cl2); IR (ZnSe) 3271, 2929, 2849, 1692, 1596, 
1212, 1023 cm-1; 1H NMR (MeOD, 600 MHz, WS-5-61_7May2012): 1H NMR (MeOD, 600 
MHz): δ 8.305/8.296 (two overlapping d, J = 4.8 Hz, total 1H, H-8), 8.258/8.256 (two 
overlapping singlet, total 1H, H-2), 6.25 (d, J = 6.0Hz, total 1H, H-1′), 5.51 (m, 1H, H-2′), 5.16 
(m, 1H, H-3), 4.52-4.47 (m, 2H), 4.34-4.21 (m, 3H), 3.83 (br m, 1H), 3.69-3.65 (m, 3H), 3.20 
(m, 1H), 2.95-2.92 (m, 1H), 2.72 (d, J = 12 Hz, total 1H), 1.96-1.87 (m, 2H), 1.76-1.66 (br m, 
1H),  1.62 (overlapping signal, s, 3H), 1.62-1.53 (overlapping signal, m, 1H), 1.41 (overlapping 
signal, s, 3H), 1.50-1.25 (br m, 6H); 13C NMR (MeOD, 150 MHz) δ 164.8, 156.0, 152.7, 148.9, 
140.4-140.3 (3 lines), 119.2, 114.2-114.15 (3 lines), 90.6-90.4 (4 lines), 85.5-85.3 (6 lines), 84.0-
83.8 (4 lines), 81.3-81.2 (3 lines), 65.9-65.8 (4 lines), 65.14-65.06 (3 lines), 62.03/62.01, 60.2, 
55.7, 53.42, 51.9-51.6 (4 lines), 39.7, 37.9/37.8, 32.9/32.8, 28.7-28.3 (5 lines), 25.0-24.9 (3 
lines), 24.15; 31P NMR (MeOD, 243MHz) δ 32.84, 32.70, 32.63; HRESI-MS: calcd for 
12C25
1H38
14N7
16O8PSNa: [M+Na]
+:650.2138; found: 650.2114.  
 
((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl hydrogen (2-hydroxy-6-((3aS,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)hexyl)phosphonate (5b): A solution of methyl ketophosphonate 
(4b, 23 mg, 37 µmol) in 2 mL of 9:1 pyridine/water was stirred at 60oC for 3 days. The solvent 
was evaporated under reduced pressure and the residue was purified by column chromatography 
using 2:1:1 of iPrOH: CH3CN: 50mM aq. NH4CO3 to afford compound 5 as a white solid (20 
mg, 89 %): mp 154-170 oC; Rf = 0.77 (2:1:1 iPrOH: CH3CN: 50mM aq NH4CO3); IR (ZnSe) 
3275 (br), 2932, 2860, 1678, 1602, 1208, 1054 cm-1; 1H NMR (MeOD, 300 MHz): δ 8.46/8.45 
(two apparent s, total 1H), 8.247/8.244 (two overlapping s, total 1H), 6.23 (d, J = 3.0 Hz, 1H), 
5.40 (dd, J = 3.0, 6.0 Hz, 1H), 5.15/5.13 (two overlapping dd, J = 2.4, 5.7 Hz, 1H), 4.52-4.46 
(bm, 2H), 4.31/4.29 (two overlapping dd, J = 4.4, 7.8 Hz, 1H), 4.13-3.97 (m, 2H), 3.78 (bm, 1H), 
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3.85-3.80 (br m, 1H), 3.36 (s, 3H), 3.16 (m, 1H), 2.91 (dt, J = 4.8, 12.3 Hz, 1H), 2.69 (d, J = 12.6 
Hz, 1H), 1.62 (apparent s, 3H, overlapping signal), 1.41 (apparent s, 3H, overlapping signal), 
1.75-1.25 (m, 10H); 13C NMR (MeOD, 75 MHz) δ 164.8, 155.9, 152.5, 149.1, 140.08/140.01 
(two apparent s), 118.9/118.8 (two overlapping s), 113.86/113.75 (two apparent singlet), 
90.6/90.4 (two apparent singlet), 85.7 (d, 3J (C,P) = 7.5 Hz), 84.4/84.2 (two apparent s), 
81.9/81.7 (two apparent s), 67.15/67.11 (two overlapping d, CHOH, 2J (C,P) = 3.0 Hz), 63.70 
(two apparent d, CH2 OP, 
2J (C,P) = 5.3 Hz), 61.98/61.96 (two overlapping s), 60.2, 55.72/55.70 
(two overlapping s), 39.7, 37.57/37.41 (two overlapping d, CH2 CHOH, 
3J (C,P) = 11.3 Hz), 
34.2/34.0 (two overlappling d, CH2 P, 
1J (C,P) = 131.3 Hz), 28.69/28.67 (two overlapping s), 
28.32/28.29 (two overlapping s), 26.11, 25.06/24.99 (two overlapping s), 24.14; 31P NMR 
(MeOD, 162MHz) δ 26.49/26.45 (two overlapping s); HRESI-MS: calcd for 
12C21
1H35
14N7
16O8Na2PS: [M+2Na]
+:658.1801; found = 658.1795. 
 
ammonium ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl (2-hydroxy-6-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)hexyl)phosphonate (6b): A solution of the ketophosphonate (5b, 17.8 mg, 0.03 mmol) in 1 
mL of 9/1 TFA/water was stirred at room temperature for 10 min. The solvent was removed 
under vacuum and the residue was washed with CH2Cl2.  The residue was treated with 50 mM 
aq. ammonium bicarbonate (0.57 mL) and the solution was evaporated to dryness. The residue 
was washed with methanol to afford a white solid ( 17 mg, 99%): Rf = 0.50 (8:1:1 iPrOH: 
CH3CN: 50 mM aq NH4OH);  
1H NMR (D2O, 600 MHz, WS-5-75): δ 8.55/8.54 (two 
overlapping s, 1H, H-8), 8.39 (s, 1H, H-2), 6.12/6.11 (two overlapping d, J = 4.8 Hz, 1H, H-1′), 
4.70 (m overlapping with D2O, H-2′), 4.50-4.43 (m, 2H, CH2CH-NH overlapping with H-3′), 
4.32 (br s, 1H, H-4′), 4.27 (ddd, J = 4.8, 7.8, 19.8 Hz, 1H, CHCH-NH) 4.20-4.09 (m, 2H, H-5′), 
3.81 (br s, 1H, CH-OH), 3.15/3.10 (two apparent pentet, J = 4.8 Hz, total 1H, S-CH), 2.86/2.83 
(two overlapping dd, J = 4.8, 13.2 Hz, 1H, SCHH), 2.64/2.62 (two overlapping d, J = 12.6 Hz, 
1H, SCHH), 1.95-1.75 (m, 2H, CH2P), 1.60-1.00 (m, 8H);
 13C NMR (D2O, 150 MHz, WS-5-75) 
δ 165.31/165.29 (two apparent s), 163.2-162.5 (4 lines), 150.0, 148.43/148.37 (two apparent s), 
144.73/144.69 (two apparent s), 142.6/142.5 (two apparent s), 119.2, 118.8/118.7 (two apparent 
s), 117.3, 115.4, 113.4, 88.5/88.3 (two apparent s), 83.9-83.7 (4 lines), 74.44/74.33 (two s), 
70.0/69.9 (two s), 67.2-67.0 (3 lines), 63.44/63.30 (two d, 2J (C,P) = 5.3 Hz, CH2OP), 
62.07/62.04 (two apparent s), 60.26/60.23 (two apparent s), 55.47/55.41 (two apparent s),  39.69, 
36.84/36.78 (two overlapping d, 2J (C,P) = 4.8 Hz, CH2CH2CH2CH2CHOH), 33.76/33.58 (two 
overlapping d, 1J (C,P) = 131 Hz, CH2P), 28.45/28.21 (two s, CH2CH2CHOH), 27.93/27.85 (two 
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s, SCHCH2), 24.65/24.47 (two s, SCHCH2CH2); 
31P NMR(D2O, 162 MHz) δ 29.87, 29.33; 
HRESI-MS (WS-5-75): calcd for 12C21
1H33
14N7
16O8PS: [M+H]
+:574.1849; found: 574.1835. 
 
((3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl hydrogen 2-oxo-6-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)hexylphosphonate (5a).   A solution of methyl ketophosphonate (4a, 19.8 mg, 
0.032 mmol) in 3 mL of 9:1 pyridine/water was stirred at 50 oC for 16 hr. The solvent was 
evaporated under reduced pressure and the residue was purified by column chromatography 
(MeCN:H2O from 8:1 to 7:1) to afford compound 5a as a white solid (10.1 mg, 53 %): []25D = -
14 (c = 0.25, MeOH); mp. 184-186 oC; Rf = 0.38 (50% MeOH/ CH2Cl2); IR (ZnSe) 3317, 3182, 
2993, 2931, 2858, 1695, 1645, 1600, 1248, 1211, 1022, 728 cm-1; 1H NMR (MeOD, 400 MHz): 
δ 8.50 (s, 1H), 8.24 (s, 1H), 6.24 (d, J = 3.4 Hz, 1H), 5.36 (dd, J = 3.4, 6.1 Hz, 1H), 5.15 (dd, J = 
2.0, 6.1 Hz, 1H), 4.50 (bs, 1H), 4.47 (dd, J = 4.4, 7.8 Hz, 1H), 4.29 (dd, J = 4.4, 7.8 Hz, 1H), 
4.11 (ddd, J = 3.7, 11.2, 3J(H,P) = 6.4 Hz, 1H), 4.05 (ddd, J = 3.9, 11.2, 3J(H,P) = 4.0 Hz, 1H) , 
3.15 (ddd, J = 4.5, 6.2, 10.7 Hz, 1H), 2.95 (d, 2J(H,P) = 21.4 Hz, 2H), 2.91 (dd, J = 5.0, 12.7 Hz, 
1H), 2.69 (d, J = 12.7 Hz, 1H), 2.66 (t, J = 7.1 Hz, 2H), 1.75-1.35 (m, 12H); 13C NMR (MeOD, 
100 MHz) δ 206.8, 164.8, 156.0, 152.6, 149.2, 140.0, 118.8, 113.8, 90.3, 85.3 (d, 3J (C,P) = 8.0 
Hz), 84.3, 81.8, 64.4 (d, 2J (C,P) = 5.0 Hz), 61.8, 60.19, 55.49, 44.4 (apparent singlet, CH2-P 
comfirm by HSQC), 42.5, 39.68, 28.06 (2C), 26.14, 24.17, 22.93; 31P NMR (MeOH, 162MHz, 
WS-3-66-Feb12-11) δ 13.25; HRESI-MS (WS-3-67): calcd for 12C241H3323Na214N716O8PS: [M-
H+2Na]+: 656.1644; found: 656.1635. 
 
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogen 2-oxo-6-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) 
hexylphosphonate (β-ketoP, 6a) A solution of the ketophosphonate (5a, 40 mg, 0.065 mmol) in 
1 mL of 9/1 TFA/water was stirred at room temperature for 15 min. The solvent was removed 
under vacuum and the residue was precipitated and washed with MeOH to obtain compound 6 as 
a white solid. Ammonium bicarbonate (NH4HCO3, 3.0 mg, 0.038mmol) was added to the white 
solid followed by 1 mL of DI water. The resulting solution was evaporated to furnish the 
ammonium salt of β-ketoP (6a) in 22.4 mg (58% for 2 steps): []25D = +40 (c = 0.07, H2O); m 
160-170 oC with color change; IR (ZnSe) 3326, 3191, 2934, 2856, 1663, 1651, 1599, 1464, 
1201, 1034 cm-1; 1H NMR (D2O, 400 MHz, WS-3-60): δ 8.50 (s, 1H), 8.33 (s, 1H), 6.07 (d, J = 
4.8 Hz, 1H), 4.61 (t, J = 4.8 Hz, 1H), 4.41 (dd, J = 4.8, 8.0 Hz, 1H), 4.38 (t, J = 4.8, 8.0 Hz, 1H), 
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4.27 (bs, 1H), 4.19 (dd, J = 4.4, 7.6 Hz, 1H), 4.1-4.0 (bm, 2H), 3.10-2.85 (m, 3H), 2.77 (dd, J = 
4.8, 12.8 Hz, 1H), 2.56 (d, J = 13.2 Hz, 1H), 2.50 (t, J = 7.2 Hz, 2H), 1.7-0.9 (m, 12H); 13C NMR 
(D2O, 100 MHz) δ 210.0 (d, 2J (C,P) = 6 Hz), 165.2, 149.9, 148.4, 144.7, 142.4, 118.6, 88.0, 
84.1 (d, 3J (C,P) = 8.0 Hz), 74.5, 70.1, 63.6 (d, 2J (C,P) = 5.0 Hz), 61.9, 60.2, 55.2, 44 (see no 
peak but confirm by HSQC from WS-3-66-Mar12), 43.1, 39.7, 27.9, 27.7, 22.7; 31P NMR(D2O, 
162MHz, WS-3-66-Feb12-11) δ 15.15; HRESI-MS (WS-3-60): calcd for 12C211H3114N716O8PS: 
[M+H]+:572.1692; found: 572.1710 and calcd for 12C21
1H30
14N7
16O8PSNa: [M+Na]
+:594.1512; 
found: 594.1523.  The 13C signal at 44 ppm, assigned as -COCH2PO3- by HSQC) was not 
observed due to deuterium exchange and subsequent splitting of the 13C signal by both D and 
31P. Acquisition of 13C spectra in aprotic solvents was hindered by limited substrate solubility. 
 
Synthesis of Biotinol-5′-AMP. 
The synthesis of Biotinol-5′-AMP was previously reported by the coupling reaction between 5′-
AMP and biotinol. Scheme S1 describes an alternative synthesis procedure adapted from 
reported literature reported (Iwashita, M.; Makide, K.; Nonomura, T.; Misumi, Y.; Otani, Y.; 
Ishida, M.; Taguchi, R.; Tsujimoto, M.; Aoki, J.; Arai, H.; Ohwada, T., J Med Chem 2009, 52, 
5837); our approach employs the phosphoramidite method to construct the phosphate diester 
moiety.   
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Scheme S1. The synthesis of Biotinol-5′-AMP  
 
 
 
Benzyl 2′,3′-O-isopropylidineadenosine-5′-N,N-diisopropylphosphoamidite was prepared 
using a reported procedure (Iwashita, 2009-see above).  Benzyl bis(diisopropylamino)phosphite 
(0.340 g, 1.00 mmol, 1equiv, prepared using a reported procedure,2 and 2′,3′-O-
isopropylidineadenosine (0.300 g, 1.00 mmol, 1 equiv) were dissolved in 6 mL of distilled 
CH2Cl2 under an atmosphere of N2. To this mixture, a solution of 1H-tetrazole (0.07 g, 1 mmol, 
1 equiv) in 2mL THF was added, resulting after a few minutes in a cloudy solution which was 
stirred for 2 h. The reaction was then quenched with 5 mL of sat. aq NaHCO3 and extracted with 
CH2Cl2 (5 mL x 2). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by column chromatography using 6:4:1 
EtOAc:Hex:NEt3 to afford a low-melting white solid (0.344 g, 63% yield): mp. 25-35 
oC; Rf = 
0.29 (40% EA in Hex); IR (ZnSe, cm-1,WS-7-97) 3321, 3168, 2967, 2926, 2866, 1644, 1597, 
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1202, 1077, 1023, 975, 734 cm-1; 1H NMR (CDCl3, 400 MHz, WS-7-97-col): δ 8.34 (s, 1H, H-
8), 8.15/8.08 (two s, total 1H, H-2), 7.40-7.22 (m, 5H), 6.20/6.17 (two d, J = 2.8 Hz, total 1H, H-
2′), 5.61 (br s, 2H, NH2), 5.29/5.20 (two dd, J = 6.0/6.4, 2.8/2.8 Hz, total 1H, H-1′), 5.02/4.98 
(two d, J = 6.4, 2.4 Hz, total 1H, H-3′), 4.78-4.61 (m 2H, H-5′), 4.53 (m 1H, H-4′), 3.96-3.73 (m, 
2H, CH2Ph), 3.66-3.52 (m, 2H, CH(CH3)2), 1.65 (s, 3H), 1.40/1.39 (two s, 3H), 1.19 (d, J = 7.2 
Hz, 3H), 1.17 (d, J = 7.2 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz, WS-7-97-col) δ 155.4, 153.2, 149.66/149.50 (two s), 139.47/139.43 (two s), 
139.16/139.09 (two s), 128.31/128.26 (two s), 127.41/127.34 (two s), 127.01/127.00 (two s), 
120.14/119.93 (two s), 114.15/114.06 (two s), 91.48/91.16 (two s), 86.36/86.27/86.18 (three s), 
84.75/84.71 (two s), 81.83/81.80 (two s), 65.68-65.39 (four lines), 65.63-63.26 (four lines), 
43.08-42.94 (four lines), 27.20/27.18 (two s), 25.32, 24.61-24.49 (five lines); HRESI-MS (WS-
7-97): calcd for 12C26
1H37
14N6
16O5PNa: [M+Na]
+:567.2461; found: 567.2477. 
 
Benzyl 2′,3′-O-isopropylidineadenosine-5′-biotinyl triphosphate: Benzyl 2′,3′-O-
isopropylidineadenosine-5′-N,N-diisopropylphosphoamidite (0.450 g, 0.83 mmol, 1.2 equiv) and 
biotinol (0.1585 g, 0.69 mmol, 1 equiv) were dissolved in 3.5 mL of distilled CH2Cl2 at rt under 
an atmosphere of N2. To this mixture, a solution of 1H-tetrazole (0.106 g, 1.38 mmol, 2.2 equiv) 
in 3.5 mL THF was added, resulting after a few minutes in a cloudy solution. The reaction was 
stirred for 45 min afterwhich was added 0.25 mL (1.38 mmol, 2.2 equiv) of t-butyl 
hydroperoxide (TBHP) in decane. The reaction mixture was stirred for an additional 2 h at rt and 
then quenched with 15 mL of sat. aq. NaHCO3. The mixture was partitioned with 10% MeOH in 
CH2Cl2 (10 mL x 3). The combined organic layers were dried over Na2SO4. The solvent was 
evaporated and the residue was purified by column chromatography using a step gradient of 
19:1:0.2 to 9:1:0.1 of CH2Cl2:MeOH:NEt3 to afford a white solid (0.4512 g, 95% yield): mp. 80-
100 oC; Rf = 0.38 (10% MeOH in CH3Cl2); IR (ZnSe, cm
-1,WS-7-97) 3319, 3203, 2938, 2852, 
1688, 1642, 1594, 1252, 1009, 752 cm-1; 1H NMR (CDCl3, 400 MHz, WS-7-97-col): δ 
8.233/8.226 (two overlapping s, total 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.72 (s, 1H), 7.45-7.29 (m, 
5H), 6.08 (m, 1H), 5.45 (m, 1H), 5.30 (m, 1H), 5.16-4.92 (m, 3H), 4.53 (m, 1H), 4.48-4.35 (m, 
2H), 4.29 (m, 1H), 4.15 (m, 1H), 3.96-3.77 (m, 2H), 3.17 (m, 1H), 2.94 (m, 1H), 2.76 (d, J = 
12.8 Hz, 1H), 5.61 (br s, 2H, NH2), 1.62 (s, 3H, overlapping signal), 1.34 (s, 3H, overlapping 
signal), 1.80-1.10 (m, 8H); 13C NMR (CDCl3, 100 MHz, WS-7-97-col) δ 164.33 (two s), 
156.45/156.38 (two s), 152.69, 148.74/148.69 (two s), 139.68/139.54 (two s), 128.61/128.57 
(two s), 127.99/127.89 (two s), 120.2, 114. 37, 91.45/91.26 (two s), 85.68/85.59 (two s), 
69.37/69.32 (two s), 67.98/67.92 (two s), 66.73/66.67 (two s), 59.87/59.81 (two s), 45.95, 
40.82/40.76 (two s), 29.69/29.62/29.11/29.03/28.96 (four s), 27.09, 25.83, 25.31; 31P 
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NMR(CDCl3, 100MHz) δ -0.55, -0.78; HRESI-MS (WS-7-99): calcd for 
12C30
1H40
14N7
16O8PSNa: [M+Na]
+:712.2294; found: 712.2280. 
 
2′,3′-O-isopropylidineadenosine-5′-biotinyl phosphate: A suspension of benzyl 2′,3′-O-
isopropylidineadenosine-5′-biotinyl triphosphate (0.150 g, 0.220 mmol) and 10% Pd/C (0.047 g, 
0.002 mmol, 0.2 equiv) in anhydrous MeOH (2 mL) was placed in a vial under an atmosphere of 
H2 and stirred at rt for 5 h. The mixture was then filtered through a plug of Celite, which was 
washed with MeOH. The filtrate was then evaporated under vacuum and the residue was purified 
by column chromatography using 5:1:1 of iPrOH:CH3CN:50mM aq. NH4HCO3 to afford white 
solid (0.101 g, 77%): mp. 110-122 oC; 1H NMR (D2O, 400 MHz, WS-7-97-col): δ 8.29 (s, 1H), 
8.12 (s, 1H), 6.15 (d, J = 3.2 Hz, 1H), 5.36 (dd, J = 6.0, 3.2 Hz, 1H), 5.13 (dd, J = 6.0, 2.0 
Hz,1H), 4.56 (br s, 1H), 4.46 (dd, J = 8.0, 4.8 Hz, 1H), 4.20 (dd, J = 8.0, 4.4 Hz, 1H), 4.05-3.88 
(m, 2H), 3.47 (m. 1H), 2.99 (m, 1H), 2.81 (dd, J = 13.2, 4.8 Hz, 1H), 2.63 (d, J = 13.2 Hz, 1H), 
1.59 (s, 3H,), 1.38 (s, 3H, overlapping signal), 1.45-1.15 (m, 4H), 1.06-0.85 (m, 4H); 13C NMR 
(MeOD, 100 MHz, WS-7-97-col) δ 164.78, 156.02, 152.66, 149.13, 140.05, 118.86, 113.85, 
90.29, 85.58/85.49 (two s), 84.19, 81.84, 65.25/65.20/65.13 (three s), 62.00, 60.20, 55.72, 53.46, 
46.31, 39.70, 30.13/30.06 (two s), 28.52/28.36 (two s), 26.16, 25.42, 24.17, 7.81; 31P 
NMR(CDCl3, 100MHz) δ 1.50; HRESI-MS (WS-7-99): calcd for 12C231H3514N716O8PS: 
[M+H]+:600.2005; found: 600.1987. This molecule has been previously reported (reference?) 
without characterization data.  
 
Biotinol adenylate: A solution of 2′,3′-O-isopropylidineadenosine-5′-biotinyl phosphate (0.190 
g, 0.317 mmol) in 1 mL of 9/1 TFA/water was stirred at room temperature for 5 min. The solvent 
was removed under vacuum and the residue was neutralized with about 1.5 mL (1.5 equiv) of 
1M aq. NH4HCO3. The resulting solution was evaporated to dryness and the residue was purified 
by column chromatography using 5:1:1 of iPrOH:CH3CN:50mM aq NH4HCO3 to afford a white 
solid (0.079 g, 45%): 1H NMR (D2O, 400 MHz, WS-8-2): δ 8.41 (s, 1H, H-8), 8.12 (s, 1H, H-2), 
6.05 (d, J = 5.6 Hz, 1H, H-1′), 4.75 (m, 1H, overlapping with D2O, H-2′), 4.50-4.40 (m, 2H, H-3′ 
overlapping with CH2CH-NH), 4.30 (m, 1H H-4′), 4.17 (dd, J = 8.0, 4.8 Hz, 1H, CHCH-NH), 
4.04 (m, 1H, H-5′), 3.64 (m, 2H, CH2CH2OP), 2.97 (m, 1H, S-CH), 2.79 (dd, J = 13, 5.2 Hz, 1H, 
SCHH), 2.60 (d, J = 13 Hz, 1H, SCHH), 1.45-1.30 (m, 3H), 1.30-1.15 (m, 1H), 1.15-0.93 (m, 
4H); 13C NMR (D2O, 100 MHz, WS-7-97-col) δ 165.24, 155.03, 152.13, 149.08, 139.94, 118.63, 
86.98, 83.94/83.85 (two s or a doublet due to coupling with P), 73.97, 70.32, 66.15/66.10 (two s 
or a doublet due to coupling with P), 64.69/64.64 (two s or a doublet due to coupling with P), 
61.89. 60.14, 55.23, 53.86, 39.63, 29.38/29.32 (two s), 27.86, 27.70, 24.60; 31P NMR (CDCl3, 
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100MHz) δ 1.38; HRESI-MS (WS-6-14): calcd for 12C201H3114N716O8PS: [M+H]+:560.1692; 
found: 560.1683. 
 
HLCS activity. This assay is based on the HLCS dependent biotinylation of the p67 
polypeptide.3 Briefly, recombinant biotin-free p67 and human HLCS and were prepared as 
described. The polypeptide p67 comprises the 67 C-terminal amino acids in PCC, including the 
biotin-binding site K694; p67 is a well-established substrate for biotinylation by HLCS.3 Briefly, 
30 nM HLCS was incubated with 2 µM p67 in 75 mM Tris-acetate (pH 7.5), 45 mM MgCl2, 7.5 
mM ATP, 0.3 mM DTT, and 20 µM biotin in the presence of 0.05 to 0.5 mM biotin β-
ketophosphonate-5-AMP (50 µl final volume) at 37ºC for 2 h; controls were incubated in the 
absence of inhibitor. Reactions were stopped by the addition of 50 µl of Tricine loading dye 
(Invitrogen) and heating at 95ºC for 10 min. Proteins were run on 16% Tricine gels and 
transferred to polyvinylidene blots. Biotinylated p67 was probed using anti-biotin and anti-goat 
conjugated secondary antibody, and was quantified using an Odyssey infrared imaging system.4 
 
Competitive inhibition assays 
These experiments use a similar approach to HLCS activity assays with some modifications.  
Briefly, 30 nM HLCS was incubated with 2 µM p67 and cofactors as described previously.  
Reactions were incubated either in the presence or absence of 250 µM inhibitor and challenged 
with increasing amounts of biotin ranging from 0-360 µM.  Reactions were stopped by addition 
of 50 µl Tricine loading dye (Invitrogen) and heating at 95ºC for 10 min, and proteins were 
analyzed by Western blot analysis as described previously.  Data presented in the paper reflects 
mean±SD of 4 replicates. 
 
IC50 and Ki Calculation  
The Michaelis-Menten constant (Km) and IC50 values were calculated using nonlinear regression 
analysis in Graph Pad Prism 6.0 software.  The Km was estimated by plotting substrate 
concentration vs. velocity obtained from enzyme activity and competition assays, and fitting the 
curve to the Michaelis-Menten equation.  The half-maximal inhibitory concentration (IC50) was 
calculated by plotting the logarithm of the concentration of substrate vs. binding and the curve 
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generated was fit to the competition binding equation, One-site-Fit-logIC50 .  Ki was calculated 
from IC50 using an online-based tool.
5 
 
Statistics  
One-way ANOVA was used to determine whether differences among treatment groups were 
significantly different.  Dunnett’s multiple comparisons t-test was used to determine if 
differences between the control and individual treatment groups were statistically significant. 
Statistical analysis was performed in Graph Pad Prism 6.0.  
 
Figure S1. Schematic view of polar interaction between biotin-5′-AMP and wild-type HCS. 
The structure of three-dimensional (3D) model of wild-type HCS bound with biotin-5′-AMP was 
obtained using the crystal structure of Biotin-protein ligase from pyrococcus horikoshii OT3 
(pdb code: 1wqw) as the structural template. The experimental basis has been described.6  
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